Literature DB >> 17173905

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review.

Seema Menon1, John Colins, Kurt T Barnhart.   

Abstract

OBJECTIVE: Successful medical management of an ectopic pregnancy is inversely associated with initial hCG level. The purpose of this publication is to assess whether there is a level of hCG above which failure rate substantially increases.
DESIGN: A systematic review and summary analysis was performed, including studies reporting methotrexate treatment outcomes as stratified by various hCG ranges.
SETTING: Academic medical center. PATIENT(S): Review of published information regarding patients treated with methotrexate. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Success and failure rate of medical management. RESULT(S): Five observational studies, including 503 women, were found that reported successes in using single-dose methotrexate stratified by initial hCG concentration. Failure rates increase with increasing hCG levels. A substantial and statistically significant increase in failure rates is seen when comparing patients who have initial hCG levels of >5,000 mIU/mL with those who have initial levels of <5,000 mIU/mL (odds ratio: 5.45; 95% confidence interval: 3.04, 9.78). The failure rate for women who had an initial concentration between 5,000 and 9,999 mIU/mL was significantly higher than that for those who had initial levels between 2,000 and 4,999 mIU/mL (odds ratio: 3.76; 95% confidence interval: 1.16, 12.33). CONCLUSION(S): Results support a substantial increase in failure of medical management with single-dose methotrexate when the initial hCG is above 5,000 mIU/mL. Methotrexate should be used with caution in patients with ectopic pregnancy who present with hCG levels above this level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17173905     DOI: 10.1016/j.fertnstert.2006.10.007

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  29 in total

Review 1.  Tubal ectopic pregnancy.

Authors:  Rajesh Varma; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2012-02-10

2.  Tubal ectopic pregnancy.

Authors:  Vinod Kumar; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2015-11-16

Review 3.  Tubal ectopic pregnancy.

Authors:  Rajesh Varma; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2009-04-20

4.  Clinical predictors of failing one dose of methotrexate for ectopic pregnancy after in vitro fertilization.

Authors:  Paula C Brady; Stacey A Missmer; Leslie V Farland; Elizabeth S Ginsburg
Journal:  J Assist Reprod Genet       Date:  2017-01-05       Impact factor: 3.412

Review 5.  Medical management of ectopic pregnancy: a comparison of regimens.

Authors:  Emelia Argyropoulos Bachman; Kurt Barnhart
Journal:  Clin Obstet Gynecol       Date:  2012-06       Impact factor: 2.190

6.  A Clinical Experience of Ectopic Pregnancies with Initial Free Intraperitoneal Fluid.

Authors:  Mehmet Akif Sargin; Murat Yassa; Bilge Dogan Taymur; Ayhan Çelik; Sibel Aydin; Emrah Orhan; Niyazi Tug
Journal:  J Clin Diagn Res       Date:  2016-08-01

7.  Predictors of Success of a Single-Dose Methotrexate in the Treatment of Ectopic Pregnancy.

Authors:  Mohamed Akhatim Alsammani; Neimat Abdalhadi Moona
Journal:  J Obstet Gynaecol India       Date:  2015-01-31

8.  Rapid β-human chorionic gonadotropin detection in urine with electric-double-layer gated field-effect transistor biosensors and a handheld device.

Authors:  Liang-Wen Liao; Po-Hsuan Chen; Shu-Yi Tsai; Adarsh Tripathi; Akhil K Paulose; Shing-Jyh Chang; Yu-Lin Wang
Journal:  Biomicrofluidics       Date:  2021-04-05       Impact factor: 2.800

9.  Ectopic pregnancy after infertility treatment.

Authors:  Madhuri Patil
Journal:  J Hum Reprod Sci       Date:  2012-05

10.  The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review.

Authors:  Monika M Skubisz; Stephen Tong
Journal:  ISRN Obstet Gynecol       Date:  2012-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.